Skip to content
The Nexus
DossierENTITY

Michelle Davey

Coverage of Michelle Davey in the Nexus archive.

Earliest in view: Jul 20 · 11:27 UTCMost recent: Jul 20 · 11:27 UTC
Co-mentioned in this coverage
FDAorganization1Hims & Hersorganization1BPC-157topic1TB-500topic1peptidestopic1Wheelorganization1Torch Capitalorganization1
Recent coverage
  • HEALTHJul 20 · 11:27 UTCFORTUNE
    The FDA’s peptide vote could create telehealth’s next multibillion-dollar market

    The FDA is considering approval for compounding pharmacies to legally mix wellness peptides like BPC-157 and TB-500, which could create a $30 billion market. Telehealth companies like Hims & Hers, which previously profited from compounded Ozempic alternatives, are positioning to expand into peptide therapies despite limited long-term safety data.

Michelle Davey · Dossier · The Nexus